Pia Klausen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pia Klausen has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
Peter Vilmann
Gastro Unit, Division of Endoscopy, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark
17 shared publicationsAnders Toxværd
Department of Pathology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark
9 shared publicationsEvangelos Kalaitzakis
Gastro Unit, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark
9 shared publications- Adrian Saftoiu
Department of Gastroenterology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
7 shared publications - Bojan Kovacevic
Copenhagen University Hospital, Denmark
7 shared publications John Gásdal Karstensen
Gastro Unit, Division of Endoscopy, Copenhagen University Hospital Herlev, Herlev, Denmark
7 shared publications
Latest Publications
- Open Access
Refining Spatial Proteomics by Mass Spectrometry: An Efficient Workflow Tailored for Archival Tissue
Background: Formalin-fixed, paraffin-embedded (FFPE) tissue remains the gold standard for extensively archiving biological specimens, providing biobanks with large repositories of retrospective potential. However, while formalin crosslinking is effective at preserving tissue, it poses significant challenges for extracting molecular information, including the proteome. Traditionally, this process required high levels of input material, which, in turn, limited the ability to preserve cell-type heterogeneity and spatial information. To address these limitations, we developed an easily adaptable and highly efficient workflow for extracting deep proteomes from low-input materials, such as biopsies used in routine histopathological diagnostics. Methods: We compared the extraction efficiency of pancreatic acinar cells identified in FFPE tissue samples stained with conventional hematoxylin-eosin (H&E) against that of cells isolated from tissue samples immunostained for the epithelial cell adhesion molecule (EpCAM) across material inputs ranging from 1,166 to 800,000 µ m 2 (estimated to 2 to 1,310 cells in volume). Cells were isolated using laser capture microdissection and subsequently analyzed using Liquid Chromatography-Tandem Mass Spectrometry. Results: Similar yields for both methods were observed, with EpCAM-positive cells yielding slightly higher results—approximately 1,200 unique protein groups at the lowest input and up to 5,900 at the highest. In cells isolated from H&E-stained tissue, ∼900 to ∼5,200 protein groups were identified. We decided that the optimal balance for our workflow, ensuring maximum protein identification while minimizing input material, lies within the range of approximately 50,000 to 100,000 µ m 2 . With these results, we tested spatial capabilities and biological relevance by isolating cancer cells from biopsies of pancreatic cancer, lung cancer, or glioblastoma, with the first two being stained with EpCAM and the latter being stained against the tumor-suppressor protein p53. We successfully identified tissue-specific protein expressions and observed prominent clustering of all cell populations. Discussion: Our results highlight the feasibility of performing spatial proteomics on FFPE tissue using minimal input material. This adaptable methodology opens up possibilities for investigating cell-type-specific biology while preserving spatial and histological information.
Open AccessRefining Spatial Proteomics by Mass Spectrometry: An Efficient Workflow Tailored for Archival Tissue
Background: Formalin-fixed, paraffin-embedded (FFPE) tissue remains the gold standard for extensively archiving biological specimens, providing biobanks with large repositories of retrospective potential. However, while formalin crosslinking is effective at preserving tissue, it poses significant challenges for extracting molecular information, including the proteome. Traditionally, this process required high levels of input material, which, in turn, limited the ability to preserve cell-type heterogeneity and spatial information. To address these limitations, we developed an easily adaptable and highly efficient workflow for extracting deep proteomes from low-input materials, such as biopsies used in routine histopathological diagnostics. Methods: We compared the extraction efficiency of pancreatic acinar cells identified in FFPE tissue samples stained with conventional hematoxylin-eosin (H&E) against that of cells isolated from tissue samples immunostained for the epithelial cell adhesion molecule (EpCAM) across material inputs ranging from 1,166 to 800,000 µ m 2 (estimated to 2 to 1,310 cells in volume). Cells were isolated using laser capture microdissection and subsequently analyzed using Liquid Chromatography-Tandem Mass Spectrometry. Results: Similar yields for both methods were observed, with EpCAM-positive cells yielding slightly higher results—approximately 1,200 unique protein groups at the lowest input and up to 5,900 at the highest. In cells isolated from H&E-stained tissue, ∼900 to ∼5,200 protein groups were identified. We decided that the optimal balance for our workflow, ensuring maximum protein identification while minimizing input material, lies within the range of approximately 50,000 to 100,000 µ m 2 . With these results, we tested spatial capabilities and biological relevance by isolating cancer cells from biopsies of pancreatic cancer, lung cancer, or glioblastoma, with the first two being stained with EpCAM and the latter being stained against the tumor-suppressor protein p53. We successfully identified tissue-specific protein expressions and observed prominent clustering of all cell populations. Discussion: Our results highlight the feasibility of performing spatial proteomics on FFPE tissue using minimal input material. This adaptable methodology opens up possibilities for investigating cell-type-specific biology while preserving spatial and histological information.
- Open Access
Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer
Cancer-associated fibroblasts (CAFs) have been shown to impact the chemosensitivity of patient-derived tumor organoids (PDTOs). However, the published literature comparing PDTO response to clinical outcome does not include CAFs in the models. Here, a co-culture model was created using PDTOs and CAFs derived from endoscopic ultrasound-guided fine-needle biopsies (EUS-FNBs) for potential use in drug screening applications. Co-cultures were established, and growth was compared to monocultures using image metrics and a commercially available assay. We were able to establish and expand validated malignant PDTOs from 19.2% of adenocarcinomas from EUS-FNBs. CAFs could be established from 25% of the samples. The viability of PDTOs in the mixed cell co-culture could be isolated using image metrics. The addition of CAFs promoted PDTO growth in half of the established co-cultures. These results show that co-cultures can be established from tiny amounts of tissue provided by EUS-FNB. An increased growth of PDTOs was shown in co-cultures, suggesting that the present setup successfully models CAF–PDTO interaction. Furthermore, we demonstrated that standard validation techniques may be insufficient to detect contamination with normal cells in PDTO cultures established from primary tumor core biopsies.
Open AccessValidation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer
Cancer-associated fibroblasts (CAFs) have been shown to impact the chemosensitivity of patient-derived tumor organoids (PDTOs). However, the published literature comparing PDTO response to clinical outcome does not include CAFs in the models. Here, a co-culture model was created using PDTOs and CAFs derived from endoscopic ultrasound-guided fine-needle biopsies (EUS-FNBs) for potential use in drug screening applications. Co-cultures were established, and growth was compared to monocultures using image metrics and a commercially available assay. We were able to establish and expand validated malignant PDTOs from 19.2% of adenocarcinomas from EUS-FNBs. CAFs could be established from 25% of the samples. The viability of PDTOs in the mixed cell co-culture could be isolated using image metrics. The addition of CAFs promoted PDTO growth in half of the established co-cultures. These results show that co-cultures can be established from tiny amounts of tissue provided by EUS-FNB. An increased growth of PDTOs was shown in co-cultures, suggesting that the present setup successfully models CAF–PDTO interaction. Furthermore, we demonstrated that standard validation techniques may be insufficient to detect contamination with normal cells in PDTO cultures established from primary tumor core biopsies.
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S24
Initial experiences with a novel EUS-FNB derived organoid coculture system for drug screening in patients with pancreatic cancer
Aims Choice of chemotherapeutic treatment based on drug screening of patient-derived tumor organoids (PDTOs) may present a breakthrough in personalized medicine. Here we present our initial experiences with a next-generation organoid model, including PDTOs and patient-derived Cancer Associated-Fibroblasts (CAFs) from pancreatic cancer derived from EUS-FNB samples to use for drug screening purposes. Methods Patients were included prospectively with the purpose of creating cocultures for drug screening. PDTO and CAF cultures were established from EUS-FNB samples obtained during diagnostic procedures. Drug screening response was measured by analysis of image metrics. Results We included 39 patients (41 biopsy samples) undergoing a diagnostic EUS-FNB procedure. PDTOs could be established in 80%, but only expanded sufficiently for a potential drug screen in 37.5 % of cases if the corresponding biopsy was diagnostic for adenocarcinoma. Similar success rates were seen for CAFs. The addition of CAFs in cocultures significantly improved organoid viability during drug screening conditions (38% difference in organoid area, p = 0.045). Conclusions Advanced organoid cocultures could be created from EUS-FNB samples from pancreatic cancer and they may provide a more accurate disease model compared with traditional monocultures. However, challenges related to growing and expanding cells from biopsies may limit their clinical potential. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S24
Initial experiences with a novel EUS-FNB derived organoid coculture system for drug screening in patients with pancreatic cancer
Aims Choice of chemotherapeutic treatment based on drug screening of patient-derived tumor organoids (PDTOs) may present a breakthrough in personalized medicine. Here we present our initial experiences with a next-generation organoid model, including PDTOs and patient-derived Cancer Associated-Fibroblasts (CAFs) from pancreatic cancer derived from EUS-FNB samples to use for drug screening purposes. Methods Patients were included prospectively with the purpose of creating cocultures for drug screening. PDTO and CAF cultures were established from EUS-FNB samples obtained during diagnostic procedures. Drug screening response was measured by analysis of image metrics. Results We included 39 patients (41 biopsy samples) undergoing a diagnostic EUS-FNB procedure. PDTOs could be established in 80%, but only expanded sufficiently for a potential drug screen in 37.5 % of cases if the corresponding biopsy was diagnostic for adenocarcinoma. Similar success rates were seen for CAFs. The addition of CAFs in cocultures significantly improved organoid viability during drug screening conditions (38% difference in organoid area, p = 0.045). Conclusions Advanced organoid cocultures could be created from EUS-FNB samples from pancreatic cancer and they may provide a more accurate disease model compared with traditional monocultures. However, challenges related to growing and expanding cells from biopsies may limit their clinical potential. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 6 November 2019
- Published by Wiley in Histopathology
- Vol. 76 (4) , 630-633
Pitfalls of histopathological evaluation of EUS‐guided microbiopsies from pancreatic cystic neoplasms
- 6 November 2019
- Published by Wiley in Histopathology
- Vol. 76 (4) , 630-633
Pitfalls of histopathological evaluation of EUS‐guided microbiopsies from pancreatic cystic neoplasms
- 6 July 2019
- Published by Wiley in Histopathology
- Vol. 75 (5) , 767-771
Next‐generation sequencing of endoscopic ultrasound guided microbiopsies from pancreatic cystic neoplasms
Aims: Interpretation of cytology samples from pancreatic cysts is challenging. A novel microbiopsy forceps used during endoscopic ultrasound examinations offers new opportunities for histological examination of tissue from pancreatic cysts as well as next‐generation sequencing. The aim of this study was to analyse the results of next‐generation sequencing of microbiopsies from pancreatic cysts.Methods and results: Microbiopsies from 27 patients were obtained, 23 of which were subjected to next‐generation sequencing. Sixteen intraductal papillary mucinous neoplasms harboured mutations in genes regulating cell cycle and repair, and three were without mutations. Most frequent mutations were found in the KRAS and GNAS genes, and these were often concomitant. Three serous cystic neoplasms were without mutations, while with regard to histology, a non‐diagnostic microbiopsy harboured a KRAS and a TP53 mutation and was deemed malignant after clinical follow‐up. Three patients underwent surgery, and the point mutations detected in the microbiopsies were confirmed in the resected specimens. We identified one resected sample with an additional GNAS mutation which was not identified in the microbiopsy.Conclusions: Next‐generation sequencing of microbiopsies may have the potential to improve diagnostic decision‐making.
- 6 July 2019
- Published by Wiley in Histopathology
- Vol. 75 (5) , 767-771
Next‐generation sequencing of endoscopic ultrasound guided microbiopsies from pancreatic cystic neoplasms
Aims: Interpretation of cytology samples from pancreatic cysts is challenging. A novel microbiopsy forceps used during endoscopic ultrasound examinations offers new opportunities for histological examination of tissue from pancreatic cysts as well as next‐generation sequencing. The aim of this study was to analyse the results of next‐generation sequencing of microbiopsies from pancreatic cysts.Methods and results: Microbiopsies from 27 patients were obtained, 23 of which were subjected to next‐generation sequencing. Sixteen intraductal papillary mucinous neoplasms harboured mutations in genes regulating cell cycle and repair, and three were without mutations. Most frequent mutations were found in the KRAS and GNAS genes, and these were often concomitant. Three serous cystic neoplasms were without mutations, while with regard to histology, a non‐diagnostic microbiopsy harboured a KRAS and a TP53 mutation and was deemed malignant after clinical follow‐up. Three patients underwent surgery, and the point mutations detected in the microbiopsies were confirmed in the resected specimens. We identified one resected sample with an additional GNAS mutation which was not identified in the microbiopsy.Conclusions: Next‐generation sequencing of microbiopsies may have the potential to improve diagnostic decision‐making.
Subtyping of intraductal papillary mucinous neoplasms – pitfalls of MUC1 immunohistochemistry
Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic ductal adenocarcinoma (PDAC). Current edition of WHO Classification of Tumors of the Digestive System recognizes four different subtypes (gastric, intestinal, pancreatobiliary, and oncocytic) and recommends analysis of mucin expression (MUC1, MUC2, MUC5AC, MUC6) as well as evaluation of architectural and cell differentiation patterns for correct classification. However, there is no consensus on MUC1 expression of IPMN‐lesions in the literature. Current recommendations are based on studies where antibodies against the core MUC1 protein or sialylated MUC1 (tumor associated MUC1), not the fully glycosylated MUC1 were used. We have recently reported that MUC1 is strongly expressed in both gastric and intestinal types IPMN specimens from the cystic wall, obtained by endoscopic ultrasound guided microbiopsy procedure. We have used a commercial MUC1 antibody, validated and recommended for diagnostic use, which recognizes fully glycosylated MUC1. Based on the above, we propose a revision of the WHO Classification, specifying that antibodies against tumor associated MUC1 should be used for IPMN subtyping.
Subtyping of intraductal papillary mucinous neoplasms – pitfalls of MUC1 immunohistochemistry
Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic ductal adenocarcinoma (PDAC). Current edition of WHO Classification of Tumors of the Digestive System recognizes four different subtypes (gastric, intestinal, pancreatobiliary, and oncocytic) and recommends analysis of mucin expression (MUC1, MUC2, MUC5AC, MUC6) as well as evaluation of architectural and cell differentiation patterns for correct classification. However, there is no consensus on MUC1 expression of IPMN‐lesions in the literature. Current recommendations are based on studies where antibodies against the core MUC1 protein or sialylated MUC1 (tumor associated MUC1), not the fully glycosylated MUC1 were used. We have recently reported that MUC1 is strongly expressed in both gastric and intestinal types IPMN specimens from the cystic wall, obtained by endoscopic ultrasound guided microbiopsy procedure. We have used a commercial MUC1 antibody, validated and recommended for diagnostic use, which recognizes fully glycosylated MUC1. Based on the above, we propose a revision of the WHO Classification, specifying that antibodies against tumor associated MUC1 should be used for IPMN subtyping.
- Open Access
- 16 July 2018
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Endoscopy
- Vol. 10 (7) , 125-129
Diagnosis of intraductal papillary mucinous neoplasm using endoscopic ultrasound guided microbiopsies: A case report
Pancreatic cysts are increasingly diagnosed due to expanding use of cross-sectional imaging, but current diagnostic modalities have limited diagnostic accuracy. Recently, a novel through-the-needle microbiopsy forceps has become available, offering the possibility of obtaining cyst-wall biopsies. We present a case of 41-year-old male with chronic pancreatitis and a 2-cm pancreatic cyst, initially considered a pseudocyst. Subsequently, endoscopic ultrasound guided microbiopsies were successfully obtained, which surprisingly revealed an intraductal papillary mucinous neoplasm of mixed subtype with low grade dysplasia. In conclusion, obtaining biopsies from the wall of the pancreatic cystic lesions with this novel instrument is feasible and, as demonstrated in this case, can possibly alter the clinical outcome. Microbiopsies offered enough cellular material, allowing supplemental gene mutation analysis, which combined with other modalities could lead to a more individual approach when treating pancreatic cysts. However, prospective studies are warranted before routine clinical implementation.
- 16 July 2018
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Endoscopy
- Vol. 10 (7) , 125-129
Open AccessDiagnosis of intraductal papillary mucinous neoplasm using endoscopic ultrasound guided microbiopsies: A case report
Pancreatic cysts are increasingly diagnosed due to expanding use of cross-sectional imaging, but current diagnostic modalities have limited diagnostic accuracy. Recently, a novel through-the-needle microbiopsy forceps has become available, offering the possibility of obtaining cyst-wall biopsies. We present a case of 41-year-old male with chronic pancreatitis and a 2-cm pancreatic cyst, initially considered a pseudocyst. Subsequently, endoscopic ultrasound guided microbiopsies were successfully obtained, which surprisingly revealed an intraductal papillary mucinous neoplasm of mixed subtype with low grade dysplasia. In conclusion, obtaining biopsies from the wall of the pancreatic cystic lesions with this novel instrument is feasible and, as demonstrated in this case, can possibly alter the clinical outcome. Microbiopsies offered enough cellular material, allowing supplemental gene mutation analysis, which combined with other modalities could lead to a more individual approach when treating pancreatic cysts. However, prospective studies are warranted before routine clinical implementation.
- 6 July 2018
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 50 (11) , 1105-1111
A novel endoscopic ultrasound-guided through-the-needle microbiopsy procedure improves diagnosis of pancreatic cystic lesions
Background Pancreatic cystic lesions represent a diagnostic dilemma as some may harbor malignancy or have potential for malignant transformation. The aim of this study was to present our experience with a novel endoscopic ultrasound (EUS)-guided microbiopsy procedure enabling procurement of tissue from the wall of the cystic lesion. Methods We collected data from 31 consecutive patients with pancreatic cystic lesions who underwent an EUS-guided microbiopsy procedure at our institution. Records were retrospectively reviewed from a prospectively maintained database. Results The technical success was 87.1 %. Diagnostic yield of microbiopsies was 71.0 %. Microbiopsies offered sufficient tissue for morphological and immunohistochemical characterization of the lesions, as well as determination of grade of dysplasia. Furthermore, evaluation of microbiopsies changed the clinical management in six patients (19.4 %). Three nonsevere adverse events were observed (9.7 %): two cases of mild infection and one case of mild pancreatitis. All three patients recovered completely. Conclusions EUS-guided microbiopsy procedure was technically feasible, with a high diagnostic yield. Further prospective studies are needed to confirm these promising results.
- 6 July 2018
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 50 (11) , 1105-1111
A novel endoscopic ultrasound-guided through-the-needle microbiopsy procedure improves diagnosis of pancreatic cystic lesions
Background Pancreatic cystic lesions represent a diagnostic dilemma as some may harbor malignancy or have potential for malignant transformation. The aim of this study was to present our experience with a novel endoscopic ultrasound (EUS)-guided microbiopsy procedure enabling procurement of tissue from the wall of the cystic lesion. Methods We collected data from 31 consecutive patients with pancreatic cystic lesions who underwent an EUS-guided microbiopsy procedure at our institution. Records were retrospectively reviewed from a prospectively maintained database. Results The technical success was 87.1 %. Diagnostic yield of microbiopsies was 71.0 %. Microbiopsies offered sufficient tissue for morphological and immunohistochemical characterization of the lesions, as well as determination of grade of dysplasia. Furthermore, evaluation of microbiopsies changed the clinical management in six patients (19.4 %). Three nonsevere adverse events were observed (9.7 %): two cases of mild infection and one case of mild pancreatitis. All three patients recovered completely. Conclusions EUS-guided microbiopsy procedure was technically feasible, with a high diagnostic yield. Further prospective studies are needed to confirm these promising results.
- 1 June 2018
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 87 (6) , AB429
Mo1283 IMMUNOHISTOCHEMICAL CLASSIFICATION OF IPMN OBTAINED BY EUS-GUIDED MICROBIOPSIES REVEALS PREDOMINANCE OF THE PANCREATOBILIARY SYBTYPE
- 1 June 2018
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 87 (6) , AB429
Mo1283 IMMUNOHISTOCHEMICAL CLASSIFICATION OF IPMN OBTAINED BY EUS-GUIDED MICROBIOPSIES REVEALS PREDOMINANCE OF THE PANCREATOBILIARY SYBTYPE